XML 179 R32.htm IDEA: XBRL DOCUMENT v3.25.1
Summary of Significant Accounting Policies (Tables)
3 Months Ended 12 Months Ended
Mar. 31, 2025
Dec. 31, 2024
Summary of Significant Accounting Policies [Abstract]    
Schedule of Derivative Liability Measured at Fair Value The table below reflects the activity of derivative liability measured at fair value for the three months ended March 31, 2025:
   Significant
Unobservable Inputs
(Level 3)
 
Balance of derivative liability as of January 1, 2025  $127,545 
Reclassification of additional paid-in capital upon conversion   (18,853)
Loss from change in the fair value of derivative liability   114,360 
Balance of derivative liability as of March 31, 2025  $223,052 
The table below reflects the activity of derivative liability measured at fair value for the years ended December 31, 2024 and 2023:
   Significant Unobservable Inputs
(Level 3)
 
Balance of derivative liability as of January 1, 2023  $
-
 
Initial fair value of derivative liability attributable to warrants issuance with May, July, and October 2023 fund raises   213,170 
Gain from change in the fair value of derivative liability   (188,374)
Balance of derivative liability as of December 31, 2023   24,796 
Initial fair value of derivative liability attributable to warrants issuance with March and June 2024 fund raises   479,468 
Reclassification of additional paid-in capital upon conversion   (2,354)
Gain from change in the fair value of derivative liability   (374,365)
Balance of derivative liability as of December 31, 2024  $127,545 
Schedule of Cash Balances by Geographic Area

At March 31, 2025 and December 31, 2024, the Company’s cash balances by geographic area were as follows:

 

Country:  March 31,
2025
   December 31,
2024
 
United States  $1,351,923    98.7%  $2,844,522    99.6%
China   17,663    1.3%   11,787    0.4%
Total cash  $1,369,586    100.0%  $2,856,309    100.0%

At December 31, 2024 and 2023, the Company’s cash balances by geographic area were as follows:

 

Country:  December 31, 2024   December 31, 2023 
United States  $2,844,522    99.6%  $280,197    98.2%
China   11,787    0.4%   5,203    1.8%
Total cash  $2,856,309    100.0%  $285,400    100.0%
Schedule of Securities that were Excluded from the Diluted Per Share

The following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive:

 

   Three Months Ended March 31, 
   2025   2024 
Options to purchase common stock   1,451,425    47,287 
Warrants to purchase common stock   171,163    60,562 
Series A convertible preferred stock (*)   
-
    60,000 
Series B convertible preferred stock (**)   
-
    194,004 
Series C convertible preferred stock (***)   1,452,282    
-
 
Series D convertible preferred stock (****)   2,074,689    
-
 
Convertible notes and related accrued interest (*****)   234,554    90,133 
Potentially dilutive securities   5,384,113    451,986 

 

(*) Assumed the Series A convertible preferred stock (“Series A Preferred Stock”) was converted into shares of common stock of the Company at a conversion price of $150.00 per share.

 

(**) Assumed the Series B convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $56.70 per share.

 

(***) Assumed the Series C convertible preferred stock (“Series C Preferred Stock”) was converted into shares of common stock of the Company at a conversion price of $2.41 per share.

 

(****) Assumed the Series D convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $2.41 per share.

 

(*****) Assumed the convertible notes were converted into shares of common stock of the Company at a conversion price of $11.25 per share for the three months ended March 31, 2025. Assumed the convertible notes were converted into shares of common stock of the Company at a conversion price of $67.50 and $22.50 and $15.00 per share for the three months ended March 31, 2024.

The following table summarizes the securities that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive:

 

   Years Ended
December 31,
 
   2024   2023 
Options to purchase common stock   52,479    56,880 
Warrants to purchase common stock   182,996    43,035 
Series A convertible preferred stock (*)   60,000    60,000 
Series B convertible preferred stock (**)   194,004    194,004 
Series C convertible preferred stock (***)   1,452,282    
-
 
Convertible notes (****)   227,269    60,740 
Potentially dilutive securities   2,169,030    414,659 

 

(*)Assumed the Series A convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $150.00 per share.

 

(**)Assumed the Series B convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $56.70 per share.

 

(***)Assumed the Series C convertible preferred stock was converted into shares of common stock of the Company at a conversion price of $2.41 per share.

 

(****)Assumed the convertible notes were converted into shares of common stock of the Company at a conversion price of $11.25 per share for the year ended December 31, 2024. Assumed the convertible notes were converted into shares of common stock of the Company at a conversion price of $67.50 and $22.50 per share for the year ended December 31, 2023.